Deals this week: Synthetic Biologics, Bayer, HitGen
Synthetic Biologics has raised $12m through the private placement of 120,000 series A preferred shares priced at $100 a share.
The US-based biotechnology company plans to use the funds for general corporate purposes.
German pharmaceutical company Bayer has signed a five-year research agreement with healthcare service provider Vanderbilt University Medical Center to develop therapies targeting kidney diseases.
HitGen and Takeda Pharmaceutical have signed an agreement, under which the former will use its advanced DNA-encoded technology to discover innovative small molecule leads and license them exclusively to Takeda.
HitGen is Chinese biotechnology company, while Takeda is a Japanese pharmaceutical company.
Amylon Therapeutics has secured seed funding from a group of institutional and private investors.
The Netherlands-based company is focused on the development of central nervous system (CNS) therapies and plans to use the funds towards the progress of its lead candidate AT-010 targeting Katwijk’s disease.
Canadian monoclonal antibody therapies developer AbCellera Biologics and UK-based pharmaceutical company GlaxoSmithKline (GSK) have signed a research agreement for the discovery of monoclonal antibodies.
AbCellera Biologics will use its single-cell antibody screening platform to discover antibodies targeting undisclosed membrane protein, while GSK will develop therapeutics based on the discovered antibodies, as part of the agreement.